OPKO Health to Participate in Two September Investment Conferences
Rhea-AI Impact
Rhea-AI Sentiment
MIAMI, Sept. 02, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences.
- 13th Annual Barrington Research Fall Conference, September 9, 2020. Management will be available for one-on-one and small group video conference calls with investors during the event.
- H.C. Wainwright 22nd Annual Global Investment Virtual Conference, September 14 - 16, 2020. Management will deliver a company presentation on Tuesday, September 15th at 10:00 a.m. ET and will be available for one-on-one meetings. A live webcast of the presentation will be available on the investor section of OPKO’s website here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
ybriggs@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
OPKO Health, Inc.
NASDAQ:OPK
OPK Rankings
OPK Latest News
OPK Stock Data
920.03M
331.18M
52.41%
25.07%
13.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
MIAMI
About OPK
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig